Extra: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
Line 42: | Line 42: | ||
! AML !! B ALL !! Burkitt || T ALL !! ETP ALL ('''[[Early T Precursor ALL (ETP-ALL)|i]]''') !! MPAL ('''[[Mixed Phenotype Acute Leukaemia (MPAL)|i]]) || H.gones ('''[[Haematogones|i]]''') | ! AML !! B ALL !! Burkitt || T ALL !! ETP ALL ('''[[Early T Precursor ALL (ETP-ALL)|i]]''') !! MPAL ('''[[Mixed Phenotype Acute Leukaemia (MPAL)|i]]) || H.gones ('''[[Haematogones|i]]''') | ||
|- | |- | ||
|style="width: 12.5%; background: #E6FAFF; color:black"|<5% | |style="width: 12.5%; background: #E6FAFF; color:black"|<5% | ||
|style="width: | |style="width: 12.5%; background: #E6FAFF; color:black"|<5% | ||
|style="width: | |style="width: 12.5%; background: #E6FAFF; color:black"|<5% | ||
|style="width: 12.5%; background: # | |style="width: 12.5%; background: #E6FAFF; color:black"|<5% | ||
|style="width: 12.5%; background: #E6FAFF; color:black"|<5% | |||
|style="width: 12.5%; background: #E6FAFF; color:black"|<5% | |||
|style="width: 12.5%; background: #E6FAFF; color:black"|<5% | |||
|- | |- | ||
|} | |} | ||
Line 62: | Line 60: | ||
! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL || LPL !! PCL | ! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL || LPL !! PCL | ||
|- | |- | ||
|style="width: 12.5%; background: # | |style="width: 12.5%; background: #E6FAFF; color:black"|<5% | ||
|style="width: 12.5%; background: #E6FAFF; color:black"|<5% | |style="width: 12.5%; background: #E6FAFF; color:black"|<5% | ||
|style="width: 12.5%; background: #E6FAFF; color:black"|<5% | |style="width: 12.5%; background: #E6FAFF; color:black"|<5% | ||
|style="width: 12.5%; background: #66e0ff; color:black"|5-20% | |style="width: 12.5%; background: #66e0ff; color:black"|5-20% | ||
|style="width: 12.5%; background: # | |style="width: 12.5%; background: #E6FAFF; color:black"|<5% | ||
|style="width: 12.5%; background: #66e0ff; color:black"|5-20% | |style="width: 12.5%; background: #66e0ff; color:black"|5-20% | ||
|style="width: 14.25%; background: #006699; color:white"|40-80% | |style="width: 14.25%; background: #006699; color:white"|40-80% | ||
|style="width: 12.5%; background: #004466; color:white"|80-100% | |||
|- | |- | ||
|} | |} | ||
<span style="font-size:90%">'''Notes:''' expression is | <span style="font-size:90%">'''Notes:''' expression is usual in myeloma, and will occur on cells with plasma cell differentiation in LPL or MZL</span> | ||
Line 91: | Line 89: | ||
|} | |} | ||
<span style="font-size:90%">'''Notes:''' limited reports are consistent with expression being uncommon in T-lymphoproliferative disorders | <span style="font-size:90%">'''Notes:''' limited reports are consistent with expression being very uncommon in T-lymphoproliferative disorders</span> | ||
---- | ---- |
Latest revision as of 20:53, 13 June 2023
- Summary
- CD138 is a marker used to identify normal or malignant plasma cells with a high level of specificity, but does not discriminate normal from abnormal plasma cells and in some cases expression in myeloma may be low compared with normal plasma cells so sensitivity can be an issue. Abberancy of expression is low, but expression may be seen in lymphoplamacytic or marginal zone lymphomas (only on those cells that have plasma cell differentiation)
Normal expression and function
CD138 is a membrane protein that supports cell adhesion or binds cytokines and chemokines. In the hematopoietic system expression of CD138 is acquired by B lymphocytes as they develop into plasma cells.
Diagnostic role
- Most often CD138 used in conjunction with CD38 to identify plasma cells in the diagnosis or monitoring of myeloma
- There is very little aberrant expression, but neoplastic plasma cells may in some cases have weak, variable, or occasionally undetectable expression
- Expression is also seen cells that have plasmacytic differentiation in lymphoplasmacytoid lymphoma or marginal zone lymphoma
Other useful information
Outside of haematopoiesis CD138 is expressed by squamous epithelium.
SUMMARY TABLES
Expression: primitive cell types Click (i) on table for additional information | ||||||
---|---|---|---|---|---|---|
AML | B ALL | Burkitt | T ALL | ETP ALL (i) | MPAL (i) | H.gones (i) |
<5% | <5% | <5% | <5% | <5% | <5% | <5% |
Expression: mature B cell neoplasms | |||||||
---|---|---|---|---|---|---|---|
CLL | MCL | FL | MZL | HCL | DLBCL | LPL | PCL |
<5% | <5% | <5% | 5-20% | <5% | 5-20% | 40-80% | 80-100% |
Notes: expression is usual in myeloma, and will occur on cells with plasma cell differentiation in LPL or MZL
Expression: mature T cell neoplasms | ||||||
---|---|---|---|---|---|---|
ATLL | CTCL Sezary | T-PLL | T-LGL | NK-LGL | ||
limited | limited | limited | limited | limited |
Notes: limited reports are consistent with expression being very uncommon in T-lymphoproliferative disorders